Core Viewpoint - The company, Lingkang Pharmaceutical Group Co., Ltd., has released its quarterly report, ensuring the accuracy and completeness of the financial information presented, and confirming that there are no false records or significant omissions [2][3]. Financial Data Summary - The financial statements for the third quarter are unaudited, indicating that the financial data may not have undergone a formal audit process [3][7]. - The company reported a total of 17,701,793 circulating shares held in its repurchase account, representing 2.45% of the total shares [6]. Shareholder Information - The report includes details on the total number of ordinary shareholders and the status of major shareholders, although specific figures for the top ten shareholders are not provided [5]. Other Important Information - There are no additional reminders or significant operational updates regarding the company's performance during the reporting period [6].

Core Viewpoint - Lingkang Pharmaceutical is a company engaged in the research, production, and sales of chemical prescription drugs, facing challenges in revenue and profitability compared to industry peers [1][2]. Group 1: Business Overview - Lingkang Pharmaceutical was established on December 24, 2003, and listed on the Shanghai Stock Exchange on May 28, 2015, with its headquarters in Shannan, Tibet [1]. - The company operates in the pharmaceutical sector, specifically in chemical drugs, and is involved in various concepts such as Helicobacter pylori, innovative drugs, and hypertension treatment [1]. Group 2: Financial Performance - For Q3 2025, Lingkang Pharmaceutical reported revenue of 282 million yuan, ranking 92nd among 110 companies in the industry, while the top company, Huadong Medicine, achieved revenue of 32.664 billion yuan [2]. - The company's net profit for the same period was -34.5031 million yuan, placing it 80th in the industry, with the leading company, Heng Rui Medicine, reporting a net profit of 5.76 billion yuan [2]. Group 3: Financial Ratios - As of Q3 2025, Lingkang Pharmaceutical's debt-to-asset ratio was 38.79%, an increase from 29.02% in the previous year and above the industry average of 35.26%, indicating rising debt pressure [3]. - The company's gross profit margin was 43.92%, slightly up from 43.06% year-on-year but still below the industry average of 57.17%, suggesting room for improvement in profitability [3]. Group 4: Executive Compensation - The chairman, Tao Lingping, received a salary of 660,000 yuan for 2024, unchanged from 2023, while the general manager, Tao Xiaogang, earned 930,000 yuan, an increase of 30,000 yuan from the previous year [4]. Group 5: Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 32.60% to 25,200, while the average number of circulating A-shares held per shareholder decreased by 24.59% to 28,600 [5].

Core Viewpoint - The company emphasizes the accuracy and completeness of its quarterly report, ensuring no false statements or omissions exist, and holds its board and management accountable for the report's content [2][3]. Financial Data - The financial statements for the third quarter are not audited, indicating that the figures presented are preliminary and subject to change [3][7]. - As of the end of the reporting period, the company holds 17,701,793 shares in its repurchase account, representing 2.45% of the total circulating shares [4]. Shareholder Information - The report does not indicate any changes in the top ten shareholders or any significant transactions involving shares lent or returned under the margin trading system [5][6]. Other Important Information - The company has not identified any significant operational issues or additional important information that investors should be aware of during the reporting period [6].

Financial Performance - The company's operating revenue for Q3 2025 reached ¥110,253,079.87, representing a year-on-year increase of 23.12%[3] - The total profit for the period was ¥1,463,459.44, with a significant decline in net profit attributable to shareholders of ¥1,230,540.25, reflecting a decrease of ¥34,503,145.52 compared to the previous year[3] - The basic and diluted earnings per share for the current period were both ¥0.0017, showing a decline from the previous year's loss of ¥0.0478[3] - Total operating revenue for the first three quarters of 2025 reached ¥281,860,683.71, a 22% increase from ¥231,030,545.43 in the same period of 2024[17] - Net profit for the first three quarters of 2025 was a loss of ¥34,503,145.52, compared to a loss of ¥46,889,888.23 in 2024, representing a 26.4% improvement[19] - Operating profit for the first three quarters of 2025 was a loss of ¥37,302,707.07, an improvement from a loss of ¥52,997,337.55 in 2024[18] - The company reported a total comprehensive loss of ¥34,503,145.52 for the first three quarters of 2025, compared to a loss of ¥46,889,888.23 in 2024[19] - Basic and diluted earnings per share for the first three quarters of 2025 were both -¥0.0478, an improvement from -¥0.0650 in 2024[19] Cash Flow and Liquidity - The net cash flow from operating activities showed a negative figure of ¥118,052,632.91, indicating cash outflows during the period[3] - Cash flow from operating activities for the first three quarters of 2025 was ¥256,887,980.39, compared to ¥238,867,039.41 in 2024, indicating a 7.5% increase[21] - The net cash flow from operating activities was -$118.05 million, compared to -$64.06 million in the previous period, indicating a decline in operational cash flow[22] - The total cash and cash equivalents at the end of the period stood at $172.79 million, down from $314.45 million at the beginning of the period, indicating a decrease in liquidity[23] - Cash outflows related to operating activities totaled $396.54 million, up from $337.60 million, highlighting increased operational expenses[22] - The company reported a cash inflow of $9.69 million from recovered investments, which was not present in the previous period, indicating a positive shift in investment recovery[22] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,201,230,248.10, down 4.31% from the previous year-end[4] - The equity attributable to shareholders decreased by 4.48% to ¥735,303,820.60 compared to the previous year-end[4] - Total liabilities decreased to ¥465,926,427.50 in 2025 from ¥485,573,776.61 in 2024, a reduction of approximately 4.5%[16] - Current liabilities totaled RMB 184,992,263.12, down from RMB 219,314,211.55, showing a reduction of about 15.6%[15] - Long-term liabilities, including bonds payable, increased to RMB 273,206,191.54 from RMB 257,991,407.31, an increase of approximately 5.2%[15] Shareholder Information - The total number of common shareholders at the end of the reporting period is 25,212[11] - Lingkang Holdings Group Co., Ltd. holds 339,652,800 shares, accounting for 47.09% of total shares, with 49,659,600 shares pledged[11] - The company repurchased 17,701,793 shares, representing 2.45% of the total circulating shares[12] - The top 10 shareholders do not have any changes in their shareholding due to margin trading activities[13] Operational Insights - The increase in operating revenue was attributed to the company's efforts in leveraging unique product potential and expanding its pharmaceutical distribution business[8] - The company has implemented refined management practices to control costs, contributing to the changes in profit figures[8] - Research and development expenses decreased to ¥5,982,143.02 in 2025 from ¥14,987,666.90 in 2024, a reduction of approximately 60%[18] Investment Activities - Total cash inflow from investment activities was $37.59 million, significantly lower than $196.54 million in the prior period, reflecting reduced investment returns[22] - Cash outflows for investment activities were $1.02 million, significantly lower than $11.44 million in the previous period, suggesting reduced capital expenditures[22] Accounting Standards - The company will not apply new accounting standards starting from 2025, maintaining current reporting practices[24]

Core Viewpoint - Lingkang Pharmaceutical Group Co., Ltd. announced that its wholly-owned subsidiary, Hainan Lingkang Pharmaceutical Co., Ltd., has been shortlisted for the 11th batch of national drug centralized procurement for its product, injectable cefoperazone sodium, which is expected to positively impact the company's market expansion and brand influence [1][3]. Group 1: Drug Procurement Announcement - The injectable cefoperazone sodium is proposed to be selected in the national centralized procurement process, with the final selection subject to confirmation by the procurement office [1]. - The procurement cycle for the selected product is set for three years, starting from the execution date in 2026 until December 31, 2028 [2]. Group 2: Financial Impact - The projected sales revenue for injectable cefoperazone sodium in 2024 is approximately 23.01 million yuan, accounting for 6.06% of the company's total revenue for that year [3]. - For the first half of 2025, the sales revenue is estimated at 1.82 million yuan, representing 1.06% of the company's revenue for that period [3]. - The price of the selected product is expected to decrease compared to current sales prices in the provinces, which may enhance market penetration and brand recognition for the company [3].

Core Viewpoint - Lingkang Pharmaceutical (603669) announced participation in the 11th batch of national centralized drug procurement organized by the National Organization for Drug Procurement Office, with its product, injectable Cefoperazone Sodium, expected to be selected for this procurement [1] Group 1 - Lingkang Pharmaceutical's wholly-owned subsidiary, Lingkang Pharmaceutical, is involved in the national drug centralized procurement process [1] - The National Organization for Drug Procurement Office has published the proposed selection results for the centralized procurement [1] - Injectable Cefoperazone Sodium from Lingkang Pharmaceutical is anticipated to be included in this procurement round [1]

| 证券代码：603669 | 证券简称：灵康药业 | 公告编号：2025-070 | | --- | --- | --- | | 债券代码：113610 | 债券简称：灵康转债 | | 灵康药业集团股份有限公司 重要内容提示： 灵康药业集团股份有限公司（以下简称"灵康药业"、"公司"）股票 自 2025 年 9 月 29 日至 2025 年 10 月 29 日已有 10 个交易日的收盘价低于当期转 股价格的 85%（5.53 元/股），存在触发《灵康药业集团股份有限公司公开发行 可转换公司债券募集说明书》（以下简称"《募集说明书》"）中规定的转股价 格向下修正条件的可能性。若触发条件，公司将于触发条件当日召开董事会审议 决定是否修正转股价格，并及时履行信息披露义务。 关于"灵康转债"预计满足转股价格修正条件的提示 性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 （二）经上海证券交易所自律监管决定书[2020]412 号文同意，公司发行的 525,000,000 元可转换公司债券于 2020 年 12 月 22 ...

Core Viewpoint - Lingkang Pharmaceutical announced participation in the 11th national centralized drug procurement, with its product, injectable cefoperazone sodium, expected to be selected for procurement, indicating potential revenue growth for the company [1] Company Summary - Lingkang Pharmaceutical's wholly-owned subsidiary, Hainan Lingkang Pharmaceutical Co., Ltd., will participate in the national centralized procurement from October 27 to October 28, 2025 [1] - The projected sales for injectable cefoperazone sodium in 2024 are approximately 23.01 million yuan, accounting for 6.06% of the company's total revenue for that year [1] - For the first half of 2025, the sales of the same product are estimated at 1.82 million yuan, representing 1.06% of the company's revenue for that period [1] - The revenue composition for Lingkang Pharmaceutical in 2024 is as follows: pharmaceuticals 84.62%, pharmaceutical distribution 12.19%, other businesses 2.7%, and hospital sales and distribution 0.48% [1] - As of the report, Lingkang Pharmaceutical has a market capitalization of 4 billion yuan [1]

Core Viewpoint - Lingkang Pharmaceutical (603669.SH) announced that its wholly-owned subsidiary, Hainan Lingkang Pharmaceutical Co., Ltd., participated in the 11th national centralized procurement organized by the National Organization for Drug Procurement Office, with its product, injectable cefoperazone sodium, expected to be selected in this procurement process [1] Group 1 - Lingkang Pharmaceutical's subsidiary is involved in a significant national drug procurement initiative [1] - The product under consideration for selection is injectable cefoperazone sodium [1]

证券代码：603669 证券简称：灵康药业 公告编号：2025-069 公司全资子公司灵康制药的注射用头孢唑肟钠2024年销售额为2,300.89万 元，占公司 2024 年度营业收入比例为 6.06%；2025 年半年度销售额为 181.83 万 元，占公司 2025 年半年度营业收入比例为 1.06%。 本次药品集中采购是国家组织的第十一批国家药品集中采购，采购周期中， 医疗机构将优先使用本次药品集中采购中选药品，并确保完成约定采购量。本次 公司全资子公司灵康制药拟中选药品的价格较拟中选省份现销售价格相比存在 一定程度下降。若拟中选产品确定中选后将签订购销合同并实施，将有利于促进 灵康药业集团股份有限公司 关于子公司参与全国药品集中采购拟中选的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 2025 年 10 月 27 日至 2025 年 10 月 28 日，灵康药业集团股份有限公司（以 下简称"公司"）全资子公司海南灵康制药有限公司（以下简称"灵康制药"） 参加了国家组织药品联合采购办公室（以下简称"联采办" ...